Development of COVID-19 therapies: Nonclinical testing considerations
Author:
- 21 May 2022
- journal article
- research article
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 132, 105189
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concernScience Translational Medicine, 2021
- Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)Toxicologic Pathology, 2020
- Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapiesNature Microbiology, 2020
- How the COVID-19 pandemic highlights the necessity of animal researchCurrent Biology, 2020
- Getting a molecule into the clinic: Nonclinical testing and starting dose considerationsRegulatory Toxicology and Pharmacology, 2017
- Dose site reactions and related findings after vaccine administration in safety studiesJournal of Applied Toxicology, 2016
- Overview of global regulatory toxicology requirements for vaccines and adjuvantsJournal of Pharmacological and Toxicological Methods, 2012